or Try an Advanced Search...

    Solid Tumors Stocks List

    Symbol Grade Name % Change
    TCRX F TScan Therapeutics, Inc. 8.12
    CGEM F Cullinan Management, Inc. 2.62
    ALXO F ALX Oncology Holdings Inc. 9.30
    RLAY F Relay Therapeutics, Inc. 2.37
    CRDF F Cardiff Oncology, Inc. -2.00
    CLRB F Cellectar Biosciences, Inc. 0.00
    ALRN F Aileron Therapeutics, Inc. -4.26
    ADCT F ADC Therapeutics SA 2.58
    INMB F INmune Bio Inc. 2.31
    ADAP F Adaptimmune Therapeutics plc 3.93
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Devices Other Shell Companies
    Related Stock Lists: Cancer Biotechnology Breast Cancer Immunotherapy Life Sciences Medicine Acute Myeloid Leukemia Advanced Solid Tumors Biology Biopharmaceutical Cell Biology Clinical Development Clinical Medicine Immune System Lymphoma Oncology Ovarian Cancer Sarcoma Stem Cell Treatment Of Breast Cancer

    Related ETFs - A few ETFs which own one or more of the above listed Solid Tumors stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 2.11
    CANC F Tema Oncology ETF 1.52
    BBC F Virtus LifeSci Biotech Clinical Trials ETF 1.25
    LRNZ A TrueMark Technology, AI & Deep Learning ETF 0.8
    XBI D SPDR S&P Biotech ETF 0.39
    View all Solid Tumors ETFs...
    Compare ETFs
    Compare BBC to LRNZ Compare CANC to BBC Compare CNCR to BBC

        Solid Tumors Stocks Recent News

        Date Stock Title
        Nov 21 ALXO ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
        Nov 20 RLAY Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
        Nov 19 RLAY Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
        Nov 19 CRDF Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
        Nov 19 CLRB Q3 2024 Cellectar Biosciences Inc Earnings Call
        Nov 18 CLRB Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript
        Nov 18 CLRB Cellectar Biosciences GAAP EPS of -$0.40 misses by $0.03
        Nov 18 CLRB Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
        Nov 18 CLRB Earnings Scheduled For November 18, 2024
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Devices Other Shell Companies
        Related Stock Lists: Cancer Clinical Medicine Medicine Advanced Solid Tumors Oncology Acute Myeloid Leukemia Biopharmaceutical Cancer Immunotherapy Cancer Treatment Immune System Tumors Of The Hematopoietic And Lymphoid Tissues Antineoplastic Drugs Biotechnology Chemotherapy Drugs Hematologic Malignancies Hematological Malignancies Immunology Immunotherapy Lymphoma
        Solid Tumors

        Solid tumors are masses of abnormal cells that form when cells in the body divide and grow uncontrollably. They are usually found in the organs, but can also form in the tissues of the body. Solid tumors can be benign (non-cancerous) or malignant (cancerous).

        Browse All Tags